



ObesityWeek® 2025

November 4-7, 2025; Atlanta, GA; Resource Hub – Draft

---

**Welcome to our resource hub for ObesityWeek® 2025!** This is a one-stop-shop for all your ObesityWeek® 2025 needs. We will be updating the resource hub daily, so check back in for the latest on this fantastic meeting.

### Table of Contents

[Useful Conference Links](#)

---

[Day-of Conference Reports](#)

---

[Top Highlights](#)

---

[Previous ObesityWeek® Coverage on CCKB](#)

---

### Useful Conference Links

1. [Conference Website](#)
2. [Conference Registration](#)
3. [Conference Program](#)
4. [Day-by-Day Conference Preview](#)

### Day-of Conference Reports

1. [Day #1 Highlights](#)
2. [Day #2 Highlights](#)
3. [Day #3 Highlights](#)
4. [Day #4 Highlights](#)

### Top Highlights

1. [Presidential Plenary](#): Drs. Daniel Bessesen, James Hill, and Robert Eckel on obesity as a chronic disease
2. [Drs. Robert Kushner, Fatima Cody Stanford, and Donna Ryan debate](#) the clinical use of the Lancet Commission’s new obesity definition
3. [Weight loss and metabolic benefits maintained](#) with de-escalation of semaglutide and tirzepatide
4. [A reduction in muscle inflammation may explain muscle mass loss](#) with GLP-1 RAs and may provide protective effects
5. [Prior weight loss attenuated tirzepatide response](#), except in people with T2D
6. [Full results of the phase 3 ATTAIN-2 trial](#): Lilly’s once-daily oral GLP-1 RA orforglipron reduces weight by up to 11% and A1c by up to 1.8% in participants T2D and overweight or obesity
7. [STEP UP trial post-hoc analysis](#): 13-20% of participants achieved a low risk cardiometabolic state in 72 weeks with semaglutide use
8. [Key Lecturers](#): Dr. Lotte Bjerre Knudsen and Dr. Philipp Scherer discuss GLP-1 RAs and adiponectin over the ages

9. [Post-hoc analysis of the OASIS-4 trial](#): Participants demonstrating  $\geq 15\%$  weight reduction experienced improved glycemic management and cardiovascular benefits
10. [Post-hoc analysis of SURMOUNT-5](#): Participants with limited physical function at baseline experienced higher quality of life scores on tirzepatide versus semaglutide when assessed by SF-36v2
11. [Full results of the phase 2 trial](#): Amylin agonist eloralintide confers up to 20% weight loss in people with obesity
12. [Post-hoc analyses of REDEFINE 1](#): CagriSema reduces blood pressure in adults with overweight or obesity and positively affects body composition
13. [Key Lecturers](#): Dr. Ziyad Al-Aly maps the neurological effectiveness and risks of GLP-1 RAs
14. [Dr. Louis Aronne delivers George A. Bray Founders Award lecture](#) on the past, present, and future of medical treatment of obesity
15. [Prof. Stephen O’Rahilly spotlights subcutaneous adipose tissue](#) as an important therapeutic target for metabolic syndrome
16. [Phase 2b QUALITY trial of enobosarm](#) shows that combination therapy with a GLP-1 RA is selective for fat loss while preserving lean mass and function
17. [Medicare GLP-1 RA prescription disparities](#): One-third of beneficiaries are eligible, yet only 5% have a claim for a GLP-1 RA

### **Previous ObesityWeek® Coverage on CCKB**

1. [ObesityWeek® 2024 Resource Hub](#)
2. [ObesityWeek® 2023 Resource Hub](#)
3. [ObesityWeek® 2022 Resource Hub](#)
4. [ObesityWeek® 2021 Full Report](#)
5. [ObesityWeek® 2020 Full Report](#)